A strategy to target TCRαβ on T cell lymphomas is in trial and relies on discriminatory targeting of TRBC1 or TRBC2, but would not be suitable to combine with CD3ε given their linked multimeric expression [31]. Here, TRBC2 is linked to T-cell non-Hodgkin lymphoma.